A Phase 2 interventional study of docetaxel and cisplatin in Nasopharyngeal Neoplasms and Carcinoma, sponsored by Sanofi. Completed at 26 sites in 14 countries. Open to participants aged 1 Month to 21 Years. Per ClinicalTrials.gov, last updated 2015-07-30.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing docetaxel in Nasopharyngeal Carcinoma — 1 open to participants now, 4 under way, 3 of them phase 3. Docetaxel · Nasopharyngeal Carcinoma.
Among the 17 studies testing docetaxel in Nasopharyngeal Carcinoma, this one is the 11th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 2, and was the 1st registered.
683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.
Browse Nasopharyngeal Carcinoma studies →1 of the 17 studies testing docetaxel in Nasopharyngeal Carcinoma is open now, in 1 country. Recruiting first, the newest first:
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–64
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.
This study: 1 Month to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 8
First in 2007; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is below the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.
Median enrollment 130 across the 17 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 9 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Nasopharyngeal Carcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing docetaxel in Nasopharyngeal Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118333Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing docetaxel in Nasopharyngeal Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma (NPC).
The secondary objectives are to determine:
Planned treatment duration:
The consolidation treatment was the same for all participants: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.
683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.
This study's enrollment of 75 is below the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.
Browse Nasopharyngeal Carcinoma studies →Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nasopharyngeal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks * Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks * 5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.
Drug: docetaxel · Drug: cisplatin · Drug: 5-fluorouracil
* Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks * 5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy. Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.
Drug: cisplatin · Drug: 5-fluorouracil
Pharmaceutical form:solution for infusion Route of administration:intravenous
Also known as: Taxotere®, XRP6976
Pharmaceutical form:solution for infusion Route of administration:intravenous
Pharmaceutical form:solution for infusion Route of administration:intravenous
Also known as: 5-FU
Number of Participants With Complete Response (CR)
CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the induction treatment and prior to the radiation treatment. CR defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.
Time frame: after the completion of the induction treatment (up to 9 weeks)
Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group
AUC estimated by Bayesian method using concentration-time data for each participant and the previously defined adult population model as prior information (with validity of the estimation verified).
Time frame: Three plasma samples: one just before then 45 minutes and 5hour after the end of cycle 1 infusion
Overall Response (OR)
OR is classified as CR, partial response (PR), stable disease (SD), progressive disease (PD) or Unknown on completion of both induction and radiation treatment and assessed according to the Modified RECIST from the NCI. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as ≥30% decrease in the sum of the longest diameters (LD) of TLs, taking as reference the disease measurement done at study entry. PD is defined as ≥20% increase in the sum of the LD of TLs, taking as a reference the smallest disease measurement recorded at study entry or the appearance of ≥1 new lesions or unequivocal progression of non-TLs. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: after the completion of the consolidation treatment (up to 18 weeks)
Overall Survival (OS) Rate
OS rate is the percentage of participants who survived 3 years after completion of consolidation treatment period. The Kaplan-Meier method was used to estimate OS rate.
Time frame: 3 years after the end of the consolidation treatment period (up to 40 months from randomization)
Participants were enrolled from November 2007 until October 2008. The study was conducted at 26 centers in 14 countries.
| Milestone | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU |
|---|---|---|
| Started | 50 | 25 |
| Completed | 47 | 23 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the induction treatment and prior to the radiation treatment. CR defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.
| participants | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU |
|---|---|---|
| Number of Participants With Complete Response (CR) | 1 | 0 |
AUC estimated by Bayesian method using concentration-time data for each participant and the previously defined adult population model as prior information (with validity of the estimation verified).
| µg*h/mL | Docetaxel/Cisplatin/5-FU |
|---|---|
| Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group | 3.43 ± 2.05 |
OR is classified as CR, partial response (PR), stable disease (SD), progressive disease (PD) or Unknown on completion of both induction and radiation treatment and assessed according to the Modified RECIST from the NCI. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as ≥30% decrease in the sum of the longest diameters (LD) of TLs, taking as reference the disease measurement done at study entry. PD is defined as ≥20% increase in the sum of the LD of TLs, taking as a reference the smallest disease measurement recorded at study entry or the appearance of ≥1 new lesions or unequivocal progression of non-TLs. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| participants | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU |
|---|---|---|
| CR | 1 | 1 |
| PR | 43 | 20 |
| SD | 2 | 1 |
| PD | 2 | 0 |
| Unknown | 0 | 0 |
| Missing | 2 | 3 |
OS rate is the percentage of participants who survived 3 years after completion of consolidation treatment period. The Kaplan-Meier method was used to estimate OS rate.
| percentage of participants | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU |
|---|---|---|
| Overall Survival (OS) Rate | 85.7 (75.9 to 95.5) | 78.0 (60.8 to 95.1) |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cisplatin/5-FU | — | 11/25 (44%) | 23/25 (92%) |
| Docetaxel /Cisplatin/5-FU | — | 20/50 (40%) | 49/50 (98%) |
| Event | Cisplatin/5-FU | Docetaxel /Cisplatin/5-FU |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 1/25 | 5/50 |
| NEUTROPENIA/NEUTROPHIL COUNTBlood and lymphatic system disorders | 2/25 | 4/50 |
| CONVULSIONNervous system disorders | 2/25 | 1/50 |
| DIARRHOEAGastrointestinal disorders | 0/25 | 3/50 |
| ANOREXIAMetabolism and nutrition disorders | 0/25 | 3/50 |
| BONE MARROW FAILUREBlood and lymphatic system disorders | 1/25 | 0/50 |
| FEBRILE BONE MARROW APLASIABlood and lymphatic system disorders | 1/25 | 0/50 |
| LEUKOPENIABlood and lymphatic system disorders | 1/25 | 0/50 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/25 | 0/50 |
| STOMATITISGastrointestinal disorders | 1/25 | 2/50 |
| Event | Cisplatin/5-FU | Docetaxel /Cisplatin/5-FU |
|---|---|---|
| VOMITINGGastrointestinal disorders | 21/25 | 47/50 |
| NAUSEAGastrointestinal disorders | 10/25 | 33/50 |
| STOMATITISGastrointestinal disorders | 5/25 | 30/50 |
| ALOPECIASkin and subcutaneous tissue disorders | 1/25 | 29/50 |
| ANOREXIAMetabolism and nutrition disorders | 5/25 | 21/50 |
| NEUTROPENIA/NEUTROPHIL COUNTBlood and lymphatic system disorders | 7/25 | 20/50 |
| WEIGHT DECREASEDInvestigations | 8/25 | 20/50 |
| DIARRHOEAGastrointestinal disorders | 3/25 | 15/50 |
| ANAEMIABlood and lymphatic system disorders | 3/25 | 14/50 |
| DYSPHAGIAGastrointestinal disorders | 7/25 | 12/50 |
ITT population: all randomized participants.
| Age, Continuous(years) | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU | Total |
|---|---|---|---|
| Median | 16 (9 to 21) | 16 (9 to 21) | 16 (9 to 21) |
| Age, Customized(participants) | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU | Total |
|---|---|---|---|
| Infants from 28 days to 23 months | 0 | 0 | 0 |
| Children from 2 years to <12 years | 4 | 1 | 5 |
| Adolescents from 12 years to <16 years | 20 | 10 | 30 |
| Adolescents >=16 | 26 | 14 | 40 |
| Sex: Female, Male(Participants) | Docetaxel /Cisplatin/5-FU | Cisplatin/5-FU | Total |
|---|---|---|---|
| Female | 15 | 6 | 21 |
| Male | 35 | 19 | 54 |
The record gives a start of Nov 2007, a primary completion of Mar 2009 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel